TNFRSF1A and amyotrophic lateral sclerosis: Thus, it is reasonable to hypothesize that controlled administration of modified forms of TNFα, specifically targeting astroglial TNFR1 during the early phase of the disease, might exert a potential therapeutic role in the context of ALS.